VR Assessment for Alcohol Related Brain Damage
Alcohol Related Brain Damage: Exploring Virtual Reality Based Cognitive Function Assessment and EEG Biomarkers. A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Much of the burden of disease related to harmful alcohol use is due to the persistent effects of alcohol on central nervous system. The concept of alcohol-related brain damage (ARBD) is important in the Addiction Psychiatry field. ARBD is a spectrum of disorders. Besides most severe forms, 50-70% of patients with alcohol use disorder suffer some kind of cognitive impairment, being mild to moderate cognitive impairment the most frequent disorders, and often the most difficult to detect. In alcoholic patients, greater cognitive impairment has been associated with less treatment compliance and fewer days of abstinence. Considering its impact, cognitive screening should be enhanced.
Recently, standard assessments have been augmented with new interactive technology. The work group of the Laboratory of Synthetic, Perceptive, Emotive and Cognitive Systems (SPECS), part of Institute for Bioengineering of Catalonia (IBEC), developed a virtual assessment of cognitive function, called the Validation Gate task, which evaluates sustained attention, working memory and executive functioning. This tool has been used so far in chronic stroke patients, showing that, in this group, depression symptoms affect performance in this task.
Similarly to chronic stroke patients, a diffuse harm of several cognitive domains in ARBD is observed. In the addiction psychiatry field, the gold standard to evaluate changes in cognitive function are still thorough neuropsychological test batteries. But performing thorough neuropsychological evaluations on all patients in daily clinical practice is highly resource consuming (need of expert neuropsychologists, time consuming). These last years scientific community has also been trying to find biomarkers of ARBD in electrophysiological tests, with no conclusive results.
In this pilot study a small number of ARBD patients and healthy people will undergo a single 30-minutes-long cognitive assessment session using the Validation Gate task to evaluate usability of this tool in Alcohol Use Disorder patients. Resting-state EEG of ARBD patients will also be recorded and compared to the ones of age-matched healthy controls in order to preliminary explore the existence of possible EEG biomarkers of ARBD.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Martina Maier, Ms
- Phone Number: 722257096
- Email: mmaier@ibecbarcelona.eu
Study Contact Backup
- Name: Belén Rubio Ballester, PhD
- Email: rballester@ibecbarcelona.eu
Study Locations
-
-
-
Barcelona, Spain, 08036
- Addictions Unit. Psychiatry and Psychology Service. Institut Clínic de Neurociències (ICN). Hospital Clínic de Barcelona. IDIBAPS
-
Contact:
- Clara Oliveras Salvà, Dr
- Phone Number: 4210 34932275400
- Email: coliveras@clinic.cat
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Alcohol Use Disorder (DSM 5) as main substance
- Positive screening for alcohol related cognitive impairment (Montreal Cognitive Assessment, MoCA < 26)
- abstinent during 15 to 90 days according to self-reports
- no severe upper limb motor disability.
- Older than 18 years old.
- abìlity to talk, understand and write in Catalan, Spanish or English.
- sign informed consent
Exclusion Criteria:
- severe cognitive incapacity that prohibits the execution of the assessment
- severe impairments like spasticity, communication disabilities (aphasia or apraxia) and perceptual or physical impairments that would interfere with the correct execution or understanding of the assessment
- history of other serious mental-health problems in acute or subacute phase
- comorbidity with severe neurological illness
- regular use of other substances (except nicotine)
- active intake of benzodiazepines
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
ARBD and depression
10 patients with ARBD and at least moderate depressive symptoms (MoCA < 26, Hamilton Depression Rating Scale ≥ 17).
Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
|
The task is to observe several moving unfilled white circles on a dark background.
The circles move in straight paths.
Every so often, a randomly selected circle will displace to a point inconsistent with its trajectory, which will look like a "jump".
The subjects' task is to press the space bar every time they detect a displacement (e.g.
jump).
A session consists of 30 minutes, it starts with 2 training blocks which are followed by 2 no-cognitive load blocks and 6 blocks with increasing cognitive load conditions.
During the assessment the eye movement as well as the key presses are registered in order to calculate early and late saccades as well as conscious reporting.
Resting-state EEG will also be recorded and compared to the ones of age-matched healthy controls.
Task-dependent EEG data will be recorded during the Validation Gate task.
|
|
ARBD and no depression
10 patients with ARBD and no clinically relevant depressive symptoms (MoCA < 26, Hamilton Depression Rating Scale < 17).
Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
|
The task is to observe several moving unfilled white circles on a dark background.
The circles move in straight paths.
Every so often, a randomly selected circle will displace to a point inconsistent with its trajectory, which will look like a "jump".
The subjects' task is to press the space bar every time they detect a displacement (e.g.
jump).
A session consists of 30 minutes, it starts with 2 training blocks which are followed by 2 no-cognitive load blocks and 6 blocks with increasing cognitive load conditions.
During the assessment the eye movement as well as the key presses are registered in order to calculate early and late saccades as well as conscious reporting.
Resting-state EEG will also be recorded and compared to the ones of age-matched healthy controls.
Task-dependent EEG data will be recorded during the Validation Gate task.
|
|
Healthy
10 healthy controls (no ARDB, no depression, no cognitive deficit).
Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
|
The task is to observe several moving unfilled white circles on a dark background.
The circles move in straight paths.
Every so often, a randomly selected circle will displace to a point inconsistent with its trajectory, which will look like a "jump".
The subjects' task is to press the space bar every time they detect a displacement (e.g.
jump).
A session consists of 30 minutes, it starts with 2 training blocks which are followed by 2 no-cognitive load blocks and 6 blocks with increasing cognitive load conditions.
During the assessment the eye movement as well as the key presses are registered in order to calculate early and late saccades as well as conscious reporting.
Resting-state EEG will also be recorded and compared to the ones of age-matched healthy controls.
Task-dependent EEG data will be recorded during the Validation Gate task.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Virtual assessment (Validation Gate task)
Time Frame: 30 minutes
|
The Validation Gate task, a visual attention task where the patient must detect discontinuities in the moving trajectory of circles on the screen.
In this task the following variables will be registered: fast and slow eye saccades as well as conscious detections.
|
30 minutes
|
|
Montreal Cognitive Assessment (MoCA)
Time Frame: 20 minutes
|
MoCA test is a screening test for cognitive impairment that explores 8 domains: visuospatial/executive ability, naming, memory, attention, language, abstraction, delayed recall, and orientation.
|
20 minutes
|
|
Hamilton Depression Rating Scale
Time Frame: 10 minutes
|
Evaluation tool of depression.
Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe.
Nine are scored from 0-2.
The summed score indicates severity (0-7 no depression, > 23 very severe depression)
|
10 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Resting State and task-dependent EEG
Time Frame: 40 minutes
|
6 minutes of EEG data during resting state and 30 minutes of EEG during the Validation Gate taks, will be acquired through the wireless sensor system ENOBIO32 of Starlab.
From these recordings the mean spectral energy in the common frequency bands will be obtained as variables to identify signatures of TCD and the theta activity in the different groups.
|
40 minutes
|
|
The alcohol, smoking and substance involvement screening test (ASSIST)
Time Frame: 10 minutes
|
The ASSIST scale is used to detect substance use and classify risk and severity for each substance.
Each question (8 questions) on the ASSIST has a set of responses to choose from, and each response has a numerical score (for instance they can range from 0 for "never" to up to 8 for "daily").
The interviewer simply circles the numerical score that corresponds to the patient's response for each question/substance.
At the end of the interview the scores for each substance are added together to produce an ASSIST score for that substance.
Low numbers mean low risk, high numbers mean high risk.
We are testing only for "Alcohol-Risk", which can have a risk-score from 0 to 31.
|
10 minutes
|
|
Alcohol Use Disorders Identification Test (AUDIT)
Time Frame: 10 minutes
|
Assessment of alcohol use
|
10 minutes
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REHABOH-VG
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.